Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful improvement in male androgenetic alopecia patients receiving clascoterone 5%, the first topical androgen receptor inhibitor, which uses the same active ingredient as the company’s acne treatment, Winlevi.
Despite a raft of government policies to turn the ship around, the latest figures show a further decline in setting up and staging commercial clinical trials in the U.K., with a 25% fall in the number of patients recruited over the past two years.
Pharvaris NV looks to start filing marketing applications in the first half of 2026 on the back of positive phase III data showing oral bradykinin B2 receptor antagonist deucrictibant hit all primary and secondary endpoints as an on-demand treatment for hereditary angioedema (HAE) attacks.
